Mike Greicius, a Stanford neurologist and expert on Alzheimer's treatments, discusses the recent surge of amyloid-clearing drugs. He critiques their effectiveness, suggesting they may cause more harm than good. Greicius highlights the skepticism among doctors regarding these drugs due to minimal cognitive benefits seen in trials. He also explores genetic factors influencing Alzheimer's risk and the shift in research focus from amyloid to tau proteins, offering a glimpse of hope for more effective therapies in the future.